Detection dogs can help endangered native wildlife find a mate – ABC News

Posted on July 20, 2020 by Prof Baldwin

Moss bounds happily through the bush showing the usual exuberance of a young labrador. Despite this looking like play, he is on a serious mission to help fight the extinction of some of our mostcritically endangered species.

Moss is a detection dog in training. Unlike other detection dogs, who might sniff out drugs or explosives, he'll be finding some of Victoria's smallest, best camouflaged and most elusive animals.

These dogs use their exceptional olfactory senses to locate everything from koalashigh in the trees, desert tortoisesburrowed deep under soiland evenwhales often more effectively than any human team could aspire to.

What makes Moss unique, however, is he'll not only find endangered species in the wild, but will also be part of a larger team helping endangered species breed in captivity. These dogs will be the first in the world to do this, starting with a ground-breaking trial with Tasmanian devils.

Moss will eventually help find the tiny, cryptic Baw Baw Frog in the wild.

Wildlife detection dogs are a veryrare type of dog they are highly motivated, engaged and energetic, but also incredibly reliable and safe around thesmallest of creatures.

And Moss is the first dog to join Zoos Victoria'sDetection Dog squad, a permanent group of highly trained dogs that will live at Healesville Sanctuary.

Moss was adopted at 14 months old, after he somewhat "failed" at being a family pet. He is a hurricane of energy with an intelligent and playful mind. He's thriving with a job to keep him occupied and new challenges for his busy brain.

One sign he was perfect for this program was his indifference to the free range chickens at his foster home. For obvious reasons, a dog who likes chasing chickens wouldn't be a good candidate for protecting some of Australia's rarest feathered treasures.

Moss will also help monitor incredibly well camouflaged plains-wanderers, which are nearly impossible to spot in the day.

Currently Moss is learning crucial foundational skills, and getting plenty of exposure to different environments. Equally important, he is developing a deep bond and trust with his handlers.

The detection dog-handler bond is crucial not only for his happiness, but also for working success and longevity. Research from 2018 found a strong bond between a handler and their dog dramaticallyimproved the dog's detection results and reduced signs of stress.

Healesville Sanctuarybreeds endangered Tasmanian Devils every yearas part of aninsurance programto support conservation and research. This program is crucial to helpprotect the devilfollowing an estimated 80% decline in the wild due to a horrific transmissible cancer,Devil Facial Tumour Disease.

But managing a predator that's shy, nocturnal and prefers to be left alone can be tricky.

Wildlife, including Tasmanian devils, need a hands-off approach where possible, so they canmaintain natural behavioursand thrive in their environment.

Tasmanian devils prefer to be left alone.Healesville Sanctuary,Author provided

In the wild, devils leave scats (faeces) at communal latrine sites and usescent for communication. Male devils can tell a female is ready to mate by smelling her scat. And we think dogs could be trained to detect this, too.

We aim to train dogs to detect an odour profile in the collected scat of female devils coming into their receptive (oestrus) periods, so we can introduce females and suitable males to breed at the optimal time. The odour profile will be further verified via laboratory analyses of hormones in the scats.

The project will also explore whether dogs can detect pregnancy and lactation in the devils.

Currently, the best way to determine if a female has young is to look in her pouch, but our preference is to remain at a distance during this important time while females settle into being new mums.

Moss with his trainer, Latoya. Moss is a ball of energy and thrives in the challenging environment of conservation detection.Healesville Sanctuary,Author provided

If the dogs are able to smell a scat sample (while never coming into contact with the devil) and identify that a female is lactating with small joeys in her pouch, we can support her for example, by increasing her food while keeping a comfortable distance.

The results from this devil breeding research could offer innovative new options for endangered species breeding programs around the world.

Wildlife detection in the field means we can more accurately monitor some of our most critically endangered species, and quickly assess the impact of catastrophic events such asbushfires.

Detection dogs are the perfect intermediary between people and wildlife they can sniff out what we can't and communicate with us as a team.

And over the next few years, the Detection Dog Squad will expand to five full-time canines. They will all be selected based on their personalities rather than specific breeds, so will likely come in all shapes and sizes.

Dogs may yet go from being man's best friend to the devil's best friend and beyond, all starting with a happy labrador named Moss.

La Toya Jamieson and Marissa Parrott both work for Zoos Victoria. This article is co-authored by Naomi Hodgens and Dr Kim Miller, also from Zoos Victoria. It first appeared on The Conversation.

Follow this link:
Detection dogs can help endangered native wildlife find a mate - ABC News

Reasons to be cheerful? Optimists live longer than pessimists – Independent.ie

Posted on July 20, 2020 by Prof Baldwin

Optimists live longer than pessimists. Considerably longer, according to research by the Boston University School of Medicine. And we're not just talking about a few extra days or weeks. In a study that involved 69,744 women and 1,429 men, researchers found that those with the highest levels of optimism had a life span that was 11 to 15pc longer than those with the lowest optimism scores. Those same high-scoring optimists also had a 50 to 70pc greater chance of achieving "exceptional longevity" - which is getting to 85 years of age.

While research has identified many risk factors for disease and premature death, we know relatively less about positive psychological factors that can promote healthy ageing," said Lewina Lee, assistant professor of psychiatry at Boston University School of Medicine, when the results were published. "This study has strong public health relevance because it suggests that optimism is one such psychological asset that has the potential to extend the human lifespan."

Being optimistic means living your life in the belief that, in general, more good things will happen than bad. It's definitely a positive way to live, but can it really help you live longer?

Well, it seems that being optimistic can reduce the chances of getting many of the conditions that normally end lives early.

In a 2015 study, researchers at the University of Illinois examined the association between optimism and heart health in 5,100 adults aged between 45 and 84. Each participant's heart health was established by measuring their blood pressure, BMI, blood sugar and cholesterol levels, and by assessing their diet, level of physical activity and tobacco use. Each of these criteria were then given a score of 0, 1 or 2 - with higher scores indicating an ideal - which were then added together to give an overall heart health score.

Alongside this, each participant completed a survey to measure their mental health, including how optimistic they were.

The researchers found that those with the highest optimism levels were twice as likely of "being in ideal cardiovascular health" as those with the lowest levels of optimism. The optimists had better cholesterol and blood sugar levels, healthier BMIs, and were more likely to be physically active and less likely to smoke.

A few years earlier, in 2011, a study by the University of Michigan found that optimism can greatly reduce the risk of stroke. By devising a scale to measure the optimism levels of 6,044 adults over 50 years old, then monitoring their health over the next two years, the researchers discovered that every one-point increase in their optimism scale equated to a 9pc reduction in stroke risk.

Optimism also reduces the risk of diabetes. An American Menopause Society study that followed the health of 140,000 post-menopause women for 14 years found that women with high levels of optimism were 12pc less likely to develop type 2 diabetes.

But in addition to reducing the chances of having a serious illness, optimism also appears to reduce the severity of some illnesses and increases the chances of recovery.

In a small-scale study carried out by the University of Texas Health Science Centre at Houston, researchers found that, in a sample of 49 stroke survivors, those with the highest levels of optimism suffered less severe strokes, had lower inflammation levels - post-stroke inflammation can further damage the brain and hamper recovery - and were less physically disabled by the stroke than those with low optimism levels.

"Our results suggest that optimistic people have a better disease outcome, thus boosting morale may be an ideal way to improve mental health and recovery after a stroke," said Yun-Ju Lai, the study's lead author.

In fact, 30 years of research have shown that optimism can positively affect our health in a multitude of ways. Optimists have better immune function. They sleep better. They heal quicker. They enjoy greater IVF success. The list goes on.

But why is this?

While the exact mechanism behind optimism's effect on our health is not known, a number of important factors have been identified.

One of those is behaviour. In general, optimists tend to adopt behaviours that make it less likely that they will have a serious illness. Take exercise, for example. A US study of 73,485 women found that those with high levels of optimism were more likely to take part in vigorous physical activity, which helps reduce the risk of heart disease. And while those same women reported a drop-off in this activity in their 50s, they still had higher levels of vigorous physical activity compared to similarly aged women with low levels of optimism.

Optimists are also better at dealing with the stressors in their lives. While pessimists have a tendency to avoid dealing with their problems directly and employ harmful coping strategies - such as excessive drinking, optimists are more likely to make plans and confront their problems head on. And if they don't succeed, they'll try again.

Optimists are also less prone to rumination and worry, which is why they rarely suffer from insomnia, and they usually sleep for six to nine hours a night, according to research by the University of Illinois.

These differences in how optimists and pessimists deal with life's stressors lead to important changes in how their bodies react to those stressors. For example, studies have found that pessimists, who tend to have higher systolic and diastolic blood pressure anyway, "tend to have larger blood pressure responses to stressors." Optimists, however, have less severe physiological reactions to the same stressful situations.

Despite all the years of research, psychologists are still not in agreement about the nature of optimism. Some believe that it's a personality trait, which they call dispositional optimism. And that, bar some fluctuations, this personality trait remains relatively stable over an individual's life course. They know this because dispositional optimism is quite easily measured, often by using a simple 10-question survey called the Revised Life Orientation Test.

But there are some psychologists who believe that optimism is a thinking style. And one of the interesting things about thinking styles is that they can be learnt.

Does that mean that pessimists could improve their health by learning to think like optimists?

"You can definitely learn optimism," says positive psychologist Dr Jolanta Burke of Maynooth University. "We have a lot of evidence suggesting this. And once you have taught someone the skills, their optimism level will keep improving.

"It's just a different way of looking at things. We can all change the way we think about things. And the great thing is, by changing your thinking you also change your physiological reactions. You change your emotions. You change your actions."

A good way of illustrating the differences in optimistic and pessimistic thinking styles is to look at how optimists and pessimists react to failure in their lives.

"Pessimists tend to blame themselves for bad things," says Jolanta. "For example, if they don't do well on a driving test they'll say, 'Oh, I'm absolutely useless at this!'

"And when you say this, that you as a person are useless at something, the chances of even trying it again are significantly reduced."

Optimists, explains Jolanta, are more likely to recognise the different factors that contributed to the test failure - such as lack of practice - and then take the steps needed to get it right next time.

Optimists also believe that every failure, every bad situation, is temporary. "And this is really important," explains Dr Burke. "If you don't think it's temporary, you don't have hope for change. And we require hope to make things happen.

"Something we've seen consistently in our research is that people with optimism keep trying. They don't give in as quickly. Pessimists, on the other hand, when they're in a bad situation, they think it's going to be like this forever, getting them so down that they're less likely to re-engage with things."

Optimists are also able to compartmentalise the bad things in their lives. "Let's say an optimist failed a test. They'll say, 'Okay, it's just a test. I'm not a failure. It's just one small aspect of my life that did not go well. Look at all the good things I have. I have friends. I have a family. I have a good job.'

"They're able to look at things from a different perspective - a larger perspective."

The good news is that there are very few complete pessimists in the world. Most of us are pretty optimistic, even when faced with a serious illness. But sometimes, we need a little help in believing that good things will happen.

"The people we surround ourselves with have a huge influence on us," says Dr Burke. "In difficult times you need other people to get you out of your thinking. It's terribly important.

"Optimism needs to be viewed as taking control of your life. Pessimism creates a lot of inertia. It's better to be optimistic."

View original post here:
Reasons to be cheerful? Optimists live longer than pessimists - Independent.ie

The importance of having a primary care provider – Craig Daily Press

Posted on July 20, 2020 by Prof Baldwin

With knowledge and training spanning the full range of medical issues, primary care providers play an important role in fostering a healthy lifestyle.

From common illnesses and common injuries, to complex illnesses and complex issues, primary care providers do a little bit of everything and serve as a great gateway to specialists, said Dr. Jon Hamilton, a primary care physician with UCHealth Primary Care in Craig.

They can help identify trends and prevent disease

A primary care provider who sees you for regular physicals is specially equipped to help spot issues.

Having your own primary care provider is very important, Hamilton said. That provider gets to know you as a person, and theyre able to notice trends that might indicate something is wrong.

For instance, they can help patients better understand their risk factors for issues from heart disease to diabetes, and to take steps for prevention.

Discussing risks of future heart disease based on family history and a patients own history goes a long way to preventing future events, Hamilton said. Watching kidney function, and talking through risk factors for tobacco or alcohol use, can help us address issues before they happen.

Theyre a family resource

With yearly exams, youre going to see the same person, and your kids can see the same person, and your parents can see the same person, year after year, Hamilton said. That really goes a long way in establishing trust.

They can do various specialized procedures

Primary care providers can take care of most urgent health issues, including stitching up lacerations.

A lot of times, patients dont understand the depth of the scope of some of the dermatological procedures we can do, Hamilton said. We can take biopsies, treat some orthopedic injuries and in certain areas, help with pregnancy and childbirth.

They can help with health screenings needed for certain jobs

If youre driving a truck or machinery for work, or trying to get your pilots license, youll likely need to pass a specific health exam to ensure you are able to perform your duties. These exams can be conducted by many primary care providers.

So many peoples work depends upon those medical exams, Hamilton said. Theres not a better person to get those from than your primary care provider, as they know your entire history.

Prep, dont stress, before a visit

Hamilton encourages patients to come to appointments with a list of concerns and questions.

Thats the best way to get what you want out of a doctors visit, Hamilton said. Ask your questions, and feel free to ask the provider who they are so you can develop that level of trust.

They become a friend

Since a primary care provider often sees patients year after year, a special relationship can build.

I enjoy sitting down and visiting with people and getting to know them, Hamilton said. And I enjoy seeing them outside of the clinic and calling them friend.

Content provided by UCHealth.

Here is the original post:
The importance of having a primary care provider - Craig Daily Press

What the Bella twins typically eat in a day – Nicki Swift

Posted on July 20, 2020 by Prof Baldwin

Nikki and Brie Bella's diet is simple: They stick to fruit, oatmeal, and eggs in the morning, and for lunch, they eat fish or chicken with some vegetables and brown rice, per Workout Info Guru. The pair noshes on fruit or sips a protein shake for a snack before they eat veggies, fish, or meat for dinner. However, the sisters made it clear that there are certain things they avoid. "I don't eat red meat," Nikki told Us Weekly in 2017. "And if I want carbs, I usually have them in the morning."

Meanwhile, Brie and her husband, Daniel Bryan, have been vegetarians "for years," as she told People in 2018. "For dinner, I'm always making something," Brie told Us Weekly. "Last night it was cauliflower wings!" Since Brie doesn't eat meat, she is "very into farm-to-table" and getting "everything from your local farmers," she told Who Say (via Sportskeeda). "I stay away from fried and processed food."

Nikki and Brie's motto is "everything in moderation" when it comes to their "healthy lifestyle," Brie told Muscle & Fitness magazine. "We never want to deprive ourselves, and we think that is the way to be in shape," she divulged. "We aren't big on diets. If you create a healthy lifestyle, then you aren't sacrificing anything."

Continue reading here:
What the Bella twins typically eat in a day - Nicki Swift

5 Amazing Health Benefits of Pumpkin – MSN Money

Posted on July 20, 2020 by Prof Baldwin

Bohemian Nomad Picturemakers - Getty Images Whether it's canned or fresh, pumpkin has many health benefits. It can help your vision, prevent cancer, support immunity, and more.

You can do lots more with pumpkin than serve it up as a Thanksgiving dessert or carve it for Halloween! If youve been overlooking this superfood, now is the time to add pumpkin to your diet (did you know pumpkin is a fruit?). For starters, its packed with antioxidants that support immune function, good vision, and heart health. It may even protect against cancer. Pumpkin packs a lot of nutritional power, says Amy Kimberlain, RDN, spokesperson for the Academy of Nutrition and Dietetics. Its also incredibly versatile and can be added to many different dishes.

Heres how to get the most from its health benefits:

Its an incredibly nutritious food that supplies you with high levels of vitamins and minerals such as vitamins A, C, and E, says Kimberlain. Adding pumpkin to your diet gives you nutritional benefits with no fat, 2 grams of protein, and 3 grams of fiber. And one cup of cooked pumpkin has only 49 calories.

Pumpkin provides 245 percent of your daily recommended intake of vitamin A, which helps your body fight off infections, says Kimberlain. It also boasts 19 percent of your daily needs for vitamin C, which helps immune cells work more efficiently and wounds heal faster.

Pumpkin also contains high levels of beta carotene, which gives this winter squash its beautiful bright orange color. In a National Eye Institute clinical trial, high doses of vitamins C, E, and beta carotene reduced the risk of progression of age-related macular degeneration. Although they didnt study pumpkin specifically, pumpkin contains all these nutrients so it makes sense to add it to your diet, says Kimberlain.

Pumpkin has high levels of potassium. One study showed that a reduction in sodium and an increase in potassium helped lower blood pressure to potentially reduce stroke risk. Also, the antioxidants in pumpkin such as vitamin C, E, and lutein may reduce inflammation linked to heart disease.

Preliminary research shows that antioxidants such as betacarotene found in high levels in pumpkin may protect against certain kinds of cancer such as lung or prostate cancer. One study also showed the protective effects of carotenoids such as beta carotene against colon cancer.

We're not talking about a pumpkin spice latte. Its totally fine to indulge in a piece of pumpkin pie or cake occasionally because all foods fit into a healthy lifestyle, says Kimberlain. But you dont have to save pumpkin for dessert! Incorporate pumpkin into meals with these healthy pumpkin recipes:

$29.23

Shop Now

It doesnt really matter! Use whatever is easier for you. Keeping a can in the pantry makes it convenient to stir into dishes without having to plan ahead, says Kimberlain. Make sure you buy canned pumpkin and not pumpkin pie mix, which contains added sugars and is meant for baking. If youre feeling ambitious, pumpkins arent that difficult to grow in your garden.

$17.96

Shop Now

If you do want to use fresh pumpkin, its super-easy to roast! Look for sugar pumpkins, which are smaller and sweeter than carving pumpkins. Wash, then cut in half or into large strips, and remove the pulp (save the seeds to roast separately!). Place pieces in a jelly roll pan, drizzle with your oil of choice, and roast at 400 degrees for 20 to 25 minutes. When you can poke a fork in easily, its done. Let cool, then scoop out the soft pumpkin with a spoon. Pumpkin also freezes well.

$14.99

Shop Now

The pumpkin seeds, which also contain antioxidants, are just as yummy! Rinse well, spread on a jelly roll pan, drizzle with olive oil, and bake at 325 degrees for about 30 minutes. Top with seasonings of your choice such as garlic powder or cayenne pepper. Or saut them in a pan on low heat until dry and crispy. Eat whole!

See the rest here:
5 Amazing Health Benefits of Pumpkin - MSN Money

Low Testosterone (Low T): Causes, Symptoms, Diagnosis …

Posted on July 19, 2020 by Prof Baldwin

What is low testosterone (male hypogonadism)?

Low testosterone (male hypogonadism) is a condition in which the testes (testicles, the male reproductive glands) do not produce enough testosterone (a male sex hormone).

In men, testosterone helps maintain and develop:

Low testosterone affects almost 40% of men aged 45 and older. It is difficult to define normal testosterone levels, because levels vary throughout the day and are affected by body mass index (BMI), nutrition, alcohol consumption, certain medications, age and illness.

As a man ages, the amount of testosterone in his body gradually drops. This natural decline starts after age 30 and continues (about 1% per year) throughout his life.

There are many other potential causes of low testosterone, including the following:

Symptoms of low testosterone depend on the age of person, and include the following:

Other changes that occur with low testosterone include:

Last reviewed by a Cleveland Clinic medical professional on 04/10/2018.

Get useful, helpful and relevant health + wellness information

Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services. Policy

Read more from the original source:
Low Testosterone (Low T): Causes, Symptoms, Diagnosis ...

Signs of Low Testosterone in Men Under 30

Posted on July 19, 2020 by Prof Baldwin

When you think of declining levels of testosterone, you might think of middle-aged or older men. But men under 30 can also experience low testosterone, or low T.

According to the Mayo Clinic, testosterone levels tend to peak in men during adolescence and early adulthood. Those levels typically decline by about 1 percent each year, starting around age 30. But in some cases, you may experience declining testosterone at a younger age.

Low T is a medical condition where your body doesnt produce enough of the hormone testosterone. Both men and women produce testosterone, but its called the male hormone because men produce a lot more of it. Its critical for many male characteristics, including the maturation of male sex organs, sperm development, muscle mass development, voice deepening, and hair growth. Low T can cause a variety of symptoms, including erectile dysfunction, infertility, muscle mass loss, fat gain, and balding.

If you think you might be experiencing low T, make an appointment with your doctor. In some cases, it is caused by unhealthy lifestyle habits that you can change. In other cases, it is caused by an underlying medical condition that requires treatment. Your doctor can help you identify the cause of your symptoms and learn how to manage them.

Some advertisements for testosterone replacement products may lead you to believe that simply feeling tired or cranky is a sign of low T. In reality, symptoms tend to be more involved than that. Regardless of your age, low T symptoms can include:

Many of these symptoms can also be caused by other medical conditions or lifestyle factors. If youre experiencing them, make an appointment with your doctor. They can help you identify the underlying cause and recommend a treatment plan.

Low T is less common among men under 30, but it can still occur. Contributing factors include:

Some cases of low T may be linked to other medical conditions, such as:

If you suspect that you might have low T, make an appointment with your doctor. They can use a simple blood test to determine your testosterone level.

If your doctor finds that your testosterone level is lower than normal, they may order additional tests or do an exam to investigate why. Your treatment plan will depend on your diagnosis and medical history. Your doctor may recommend lifestyle changes or testosterone replacement therapy.

You should always talk to your doctor before taking new medications, including testosterone replacement therapy and supplements. According to research published in PLOSOne, testosterone therapy may increase your risk of heart attack, particularly if you already have heart disease. Your doctor can help you understand the potential benefits and risks of different treatment options.

Monsoon immunity booster: Rev up healthy living with these tips – Hindustan Times

Posted on July 19, 2020 by Prof Baldwin

Monsoon immunity booster: Rev up healthy living with these tips - more lifestyle - Hindustan Times "; forYoudata += ""; forYoudata += ""; forYoudata += ""; count++; if (i === 7) { return false; } }); forYouApiResponse=forYoudata; $(forutxt).html('Recommended for you'); $(foruContent).html(forYoudata); } } }); } else if(forYouApiResponse!=''){ $(forutxt).html('Recommended for you'); $(foruContent).html(forYouApiResponse); } } function getUserData(){ $.ajax({ url:"https://www.hindustantimes.com/newsletter/get-active-subscription?usertoken="+user_token, type:"GET", dataType:"json", success: function(res){ if(res.length>0) { $("[id^=loggedin]").each(function(){ $(this).hide(); }); } } }); } function postUserData(payLoad, elm){ var msgelm=$(elm).parents(".subscribe-update").nextAll("#thankumsg"); $.ajax({ url:"https://www.hindustantimes.com/newsletter/subscribe", type:"POST", data:payLoad, contentType: "application/json", dataType: "json", success: function(res){ if(res.success===true){ $(msgelm).show(); $("[id^=loggedin]").each(function(){ $(this).css("display","none"); }); $("[id^=loggedout]").each(function(){ $(this).css("display","none"); }); } else if(res.exceptionResponse.alreadySubscribed===true){ $(msgelm).show(); $("[id^=loggedin]").each(function(){ $(this).css("display","none"); }); $("[id^=loggedout]").each(function(){ $(this).css("display","none"); }); $(msgelm).find(".subscribed-successfully:first span.msg").text(res.exceptionResponse.message); } } }); }function captchverification(captchaResponse) {$('#captchaResponse').value = captchaResponse;$("#captcha-div").removeClass("block");$("body").removeAttr("style");var payLoad=JSON.stringify({ "domain": "HT", "emailId": email, "googleCaptcha": captchaResponse, "subscriptionTypes": [ "daily" ] });postUserData(payLoad,activeElm);} function subscribeNewsletter(inputText) { activeElm=inputText; var mailformat = /^w+([.-]?w+)*@w+([.-]?w+)*(.w{2,3})+$/; if(inputText.val().match(mailformat)) { inputText.focus(); email=inputText.val(); $("#captcha-div").addClass("block"); $("body").css("overflow","hidden"); return true; } else { alert("You have entered an invalid email address!"); inputText.focus(); return false; } } //DFP Ads var $dfpRightAd1 = $('.dfp-rightAd1-' + storyUuid); var $dfpRightAd2 = $('.dfp-rightAd2-' + storyUuid); var $dfpRightAd3 = $('.dfp-rightAd3-' + storyUuid); var $dfpRightAd4 = $('.dfp-rightAd4-' + storyUuid); var $dfpRightAd5 = $('.dfp-rightAd5-' + storyUuid); var $dfpStoryAd1 = $('.dfp-storyAd1-' + storyUuid); var $dfpStoryAd2 = $('.dfp-storyAd2-' + storyUuid); var $dfpStoryAd3 = $('.dfp-storyAd3-' + storyUuid); var $dfpStoryAd4 = $('.dfp-storyAd4-' + storyUuid); var $dfpStoryAd5 = $('.dfp-storyAd5-' + storyUuid); var $centerAd = $('.centerAd-' + storyUuid); getPersonlizeData(''); displayAd($dfpRightAd1,'/1055314/HT_StoryPages_300x250_Top',[[300, 250], [300, 600]]); displayAd($dfpRightAd2,'/3106570/HT_Desk_Story_BS_Multisize',['fluid', [300, 100]]); var rightMiddleScrollHandler = function () { if ($dfpRightAd3.isInViewport()) { displayAd($dfpRightAd3, '/1055314/HT_StoryPages_300x250_Middle', [[300, 250], [300, 600]]); $(window).off("scroll", rightMiddleScrollHandler); } } $(window).on("scroll", rightMiddleScrollHandler); var rightTabRepTopScrollHandler = function () { if ($dfpRightAd4.isInViewport()) { displayAd($dfpRightAd4, '/1055314/HT_Desk_Story_TabRep_Top_Multisize', [[300, 250], [300, 600]]); $(window).off("scroll", rightTabRepTopScrollHandler); } } $(window).on("scroll", rightTabRepTopScrollHandler); var rightTabRepBottomScrollHandler = function () { if ($dfpRightAd5.isInViewport()) { displayAd($dfpRightAd5, '/1055314/HT_Desk_Story_TabRep_Bottom_Multisize', [300, 250]); $(window).off("scroll", rightTabRepBottomScrollHandler); } } $(window).on("scroll", rightTabRepBottomScrollHandler); var storyCenterScrollHandler = function () { if ($centerAd.isInViewport()) { displayAd($centerAd, '/1055314/HT_Desk_Story_ES_Top_728x90', [728, 90]); $(window).off("scroll", storyCenterScrollHandler); } } $(window).on("scroll", storyCenterScrollHandler); //Inline story ads var storyAd1ScrollHandler = function () { if ($dfpStoryAd1.isInViewport()) { displayAd($dfpStoryAd1, storyAdList[0].ad, [728, 90]); $(window).off("scroll", storyAd1ScrollHandler); } } $(window).on("scroll", storyAd1ScrollHandler); var storyAd2ScrollHandler = function () { if ($dfpStoryAd2.isInViewport()) { displayAd($dfpStoryAd2, storyAdList[1].ad, [728, 90]); $(window).off("scroll", storyAd2ScrollHandler); } } $(window).on("scroll", storyAd2ScrollHandler); var storyAd3ScrollHandler = function () { if ($dfpStoryAd3.isInViewport()) { displayAd($dfpStoryAd3, storyAdList[2].ad, [728, 90]); $(window).off("scroll", storyAd3ScrollHandler); } } $(window).on("scroll", storyAd3ScrollHandler); var storyAd4ScrollHandler = function () { if ($dfpStoryAd4.isInViewport()) { displayAd($dfpStoryAd4, storyAdList[3].ad, [728, 90]); $(window).off("scroll", storyAd4ScrollHandler); } } $(window).on("scroll", storyAd4ScrollHandler); var storyAd5ScrollHandler = function () { if ($dfpStoryAd5.isInViewport()) { displayAd($dfpStoryAd5, storyAdList[4].ad, [728, 90]); $(window).off("scroll", storyAd5ScrollHandler); } } $(window).on("scroll", storyAd5ScrollHandler); validateUser($("#loggedin"),$("#loggedout")); if(user_token){ $("#loggedin .subscribe-text").html("Subscribe to get our daily newsletter in your inbox"); $("#loginSub").click(function(){ var udata=JSON.stringify({ "domain": "HT", "userToken": user_token, "googleCaptcha": "string", "subscriptionTypes": [ "daily" ] }); postUserData(udata,this); }); }else{ $("#loggedout .subscribe-text").html("Enter your email to get our daily newsletter in your inbox"); $("#subscribeBtn").click(function(){ subscribeNewsletter($(this).prev()); }); } function ScrollMe(uuid) {var id = uuid.replace('story_','').trim(); id = id +"_story";var newid = uuid.trim();$('#ulInfinite').each(function() {var phrase = '';$(this).find('li').each(function(j, lix) {var myid = $(lix).attr('id');if (myid.trim() == newid.trim())$(lix).addClass("active");else$(lix).removeClass("active");});});var element = document.getElementById(id);element.scrollIntoView();element.scrollIntoView({behavior : "auto",block : "start",inline : "nearest"});$('html, body').animate({scrollTop : $("#" + newid).offset().top - 800}, 800, 'swing');}function InfiniteScroll() {var nextURL = listUrl[urlCount];var $container = $('.articles').infiniteScroll({path : function() {return nextURL;},append : '.article',status : '.scroller-status',hideNav : '.pagination',loadOnScroll : false,scrollThreshold : false});$container.infiniteScroll('loadNextPage');$container.on('history.infiniteScroll', function(event, title, path) {var currentID = "article_" + getStoryIdByUrl('https://www.hindustantimes.com/more-lifestyle/monsoon-immunity-booster-rev-up-healthy-living-with-these-tips/story-XIAFfwkt8oRzV96jmvHeNM.html');var articleID = "article_" + getStoryIdByUrl(path);document.title = title;var temp = path.replace('.html', '').split('-');temp = temp.reverse();var forNid = temp[0].trim();$('#ulInfinite li').removeClass("active");$('#story_' + forNid).addClass("active");var n = gatag.includes(articleID, 0);if(n==false){gatag.push(articleID);showSkippablePopup();ga('send', {hitType : 'pageview',location : window.location.hostname.trim(),title : title.trim(),page : window.location.pathname.trim(),dimension15 : title});}window.snowplow("trackPageView", title);window.snowplow('resetPagePing');if (typeof COMSCORE != 'undefined'&& typeof COMSCORE.beacon !== 'undefined') {COMSCORE.beacon({c1 : "2",c2 : "6035286"});}});$container.on('load.infiniteScroll', function(event, response, path) {urlCount++;});var counter = 1;var uuid;$container.on('append.infiniteScroll', function(event, response, path, items) {uuid= $(items).find('.get-uuid').val();var elmLogin=$(items).find('#loggedin');var elmLogout=$(items).find('#loggedout');getPersonlizeData(items); validateUser(elmLogin,elmLogout); if(user_token){ getUserData(); $(elmLogin).find(".subscribe-text").html("Subscribe to get our daily newsletter in your inbox"); $(items).find("#loginSub").click(function(){ var udata=JSON.stringify({ "domain": "HT", "userToken": user_token, "googleCaptcha": "string", "subscriptionTypes": [ "daily" ] }); postUserData(udata, this); }); }else{ $(elmLogout).find(".subscribe-text").html("Enter your email to get our daily newsletter in your inbox"); $(items).find("#subscribeBtn").click(function(){ subscribeNewsletter($(this).prev()); }); }var $dfpRightAd1ES = $(items).find('.dfp-rightAd1-'+uuid); var $dfpRightAd3ES = $(items).find('.dfp-rightAd3-'+uuid); var $dfpRightAd4ES = $(items).find('.dfp-rightAd4-'+uuid); var $dfpRightAd5ES = $(items).find('.dfp-rightAd5-'+uuid); var $centerAdES = $(items).find('.centerAd-' + uuid); var $dfpStoryAd1ES = $('.dfp-storyAd1-' + uuid);var $dfpStoryAd2ES = $('.dfp-storyAd2-' + uuid); var $dfpStoryAd3ES = $('.dfp-storyAd3-' + uuid); var $dfpStoryAd4ES = $('.dfp-storyAd4-' + uuid); var $dfpStoryAd5ES = $('.dfp-storyAd5-' + uuid); var isVideoExists = $(items).find('.video-js'); var isVideo=false; if (isVideoExists.length > 0) { isVideo=true; } var rightESTopScrollHandler = function () { if ($dfpRightAd1ES.isInViewport()) { displayAd($dfpRightAd1ES, rightAdList[0].ad, rightAdList[0].adsizes); $(window).off("scroll", rightESTopScrollHandler); } } $(window).on("scroll", rightESTopScrollHandler); var rightESMiddleScrollHandler = function () { if ($dfpRightAd3ES.isInViewport()) { displayAd($dfpRightAd3ES, rightAdList[1].ad, rightAdList[1].adsizes); $(window).off("scroll", rightESMiddleScrollHandler); } } $(window).on("scroll", rightESMiddleScrollHandler); var rightESTabRepTopScrollHandler = function () { if ($dfpRightAd4ES.isInViewport()) { displayAd($dfpRightAd4ES, rightAdList[2].ad, rightAdList[2].adsizes); $(window).off("scroll", rightESTabRepTopScrollHandler); } } $(window).on("scroll", rightESTabRepTopScrollHandler); var rightESTabRepBottomScrollHandler = function () { if ($dfpRightAd5ES.isInViewport()) { displayAd($dfpRightAd5ES, rightAdList[3].ad, rightAdList[3].adsizes); $(window).off("scroll", rightESTabRepBottomScrollHandler); } } $(window).on("scroll", rightESTabRepBottomScrollHandler); var storyCenterScrollHandler = function () { if ($centerAdES.isInViewport()) { displayAd($centerAdES, '/1055314/HT_Desk_Story_ES_Top_728x90', [728, 90]); $(window).off("scroll", storyCenterScrollHandler); } } $(window).on("scroll", storyCenterScrollHandler); //Story Inline ads var storyESAd1ScrollHandler = function () { if ($dfpStoryAd1ES.isInViewport()) { displayAd($dfpStoryAd1ES, storyAdList[0].ad2, [728, 90]); $(window).off("scroll", storyESAd1ScrollHandler); } } $(window).on("scroll", storyESAd1ScrollHandler); var storyESAd2ScrollHandler = function () { if ($dfpStoryAd2ES.isInViewport()) { displayAd($dfpStoryAd2ES, storyAdList[1].ad2, [728, 90]); $(window).off("scroll", storyESAd2ScrollHandler); } } $(window).on("scroll", storyESAd2ScrollHandler); var storyESAd3ScrollHandler = function () { if ($dfpStoryAd3ES.isInViewport()) { displayAd($dfpStoryAd3ES, storyAdList[2].ad2, [728, 90]); $(window).off("scroll", storyESAd3ScrollHandler); } } $(window).on("scroll", storyESAd3ScrollHandler); var storyESAd4ScrollHandler = function () { if ($dfpStoryAd4ES.isInViewport()) { displayAd($dfpStoryAd4ES, storyAdList[3].ad, [728, 90]); $(window).off("scroll", storyESAd4ScrollHandler); } } $(window).on("scroll", storyESAd4ScrollHandler); var storyESAd5ScrollHandler = function () { if ($dfpStoryAd5ES.isInViewport()) { displayAd($dfpStoryAd5ES, storyAdList[4].ad, [728, 90]); $(window).off("scroll", storyESAd5ScrollHandler); } } $(window).on("scroll", storyESAd5ScrollHandler); counter++;if (urlCount = n && o = n ? t.play() : t.pause()) : console.log("iOS") }) }); }}else if(isVideo){$(items).find("video[id^='myPlayerID_']").each(function(t, e) {var n = "myPlayerID_" + $(e).attr("data-video-id");bc(n), videojs(n).ready(function() {this.scrollIntoView()}) });}$(items).find("div[id^='right-swiper-']").each(function(i, e) {var swipID = $(e).attr("id");var storySwiper = new Swiper('#' + swipID, {pagination : {el : '.swiper-pagination',clickable : true},preloadImages : false,lazyLoading : true,simulateTouch : false,autoplay : {delay : 3000,}});});var ind = 0;$(items).find('.read-more').each(function(ind, obj) {ind = ind + 1;var html = $(items).find("#inlineStory" + ind).html();$(this).html(html);});$(items).find('img.lazy').each(function(i, e) {$(e).lazyload({effect : "fadeIn",effectTime : 20,threshold : 200,failurelimit : 0});});//getSeoContent(items);});}var reqOpen = true;$(document).bind("scroll",function() {var viewport = {top : $(document).scrollTop(),left : $(document).scrollLeft()};viewport.bottom = viewport.top + $(document).height();lastScrollTop = viewport.top;var bot = viewport.bottom - $(document).height();if (viewport.top > 200 && (showInfinite)) {if(isCorona && !loaded){var s= document.createElement('script');s.setAttribute('async','');s.src="https://chat.amplify.ai/plugin/5e77327dd8722a5cf17170be/chat_plugin.js?pluginId=5e77327dd8722a5cf17170be";document.getElementsByTagName('head')[0].appendChild(s);loaded=true;}$('.footer-scroll-main').show();if (reqOpen == true) {$('#ulInfinite li:first').addClass("active");$('#ulInfinite li .stroy-link').each(function(i, t) {if(i>0){listUrl.push($(t).html());}});InfiniteScroll();reqOpen = false;} } else if (bot

Excerpt from:
Monsoon immunity booster: Rev up healthy living with these tips - Hindustan Times

Healthy Living: What you need to know about the Menopause – Longford Leader

Posted on July 19, 2020 by Prof Baldwin

The perimenopause can be one of the trickiest times for women to get their head around. One minute youre busy having a family and all that goes with it and all of a sudden, the years sneak up on you and you dont quiet feel like the woman you once were!

You may notice your energy levels have dropped and some days youre literally dragging yourself through the day, youve lost your get up and go for no reason, you cant seem to shift that foggy feeling in your brain and the scales is moving in the wrong direction even though your diet hasnt changed!

Welcome to the menopause, well technically the term menopause is inaccurate because it represents the end of symptoms, whereas the stage that most women struggle through is called peri-menopause, which can last anything from two to ten years until the last period.

The average age of menopause is 51. You officially reach menopause when you have had no periods for 12 consecutive months.

Women typically start to experience perimenopause in their 40s and for some the only sign is that your periods start to become more irregular, this is due to the fact that in the perimenopause, Progesterone levels fall rapidly as you stop ovulating as regularly. the levels of one of the main female sex hormones, oestrogen, rises and falls unevenly and its falling at a slower rate than progesterone, meaning you can end up being oestrogen dominant, thats a ratio of too much oestrogen to progesterone. This is usually whats behind many of the typical symptoms experienced during the transition to menopause. The stress hormone cortisol can also increase making sleep more difficult and leading to weight gain.

The thyroid comes under increased pressure, and low levels of thyroid hormones can bring mood changes, weight increases, constipation and a sluggish feeling.

Your hormones work together synergistically. When one or more is out of kilter, there can be an effect on the others, too.

The length of time between periods may be longer or shorter, your flow may be light to really heavy and with worse PMS than ever before, and you may even skip some periods only for them to return out of the blue with a vengeance.

You might also experience some of the symptoms traditionally associated with the menopause, like night sweats, hot flushes, sleep problems, mood swings, more UTIs like cystitis and vaginal dryness, poor memory, brain fog, cravings, bloating, loss of sex drive and irritability. Around this time, you might begin to notice your waistline is expanding and you just cant seem to shift that fat around the middle. Once women hit their 40s, they typically gain an average of 1lb a year so you could easily be a stone heavier by the time you reach 54.

Remember going through the peri-menopause is not an illness, it is the most natural thing in the world, although if your experiencing it right now you might be thinking this is anything but natural!! but you do have some control over managing symptoms. Its all about making some changes to your diet, stepping up your self care and taking action to reduce stress, and moving gently.

Diet

It really is important to start taking a closer look at your diet as Unfortunately when we reach this part of our life we just cant get away with eating the way we did when we were younger, as The drop in oestrogen levels that occurs during menopause has a side effect of redistributing body fat and excess pounds start to settle around the waist. On top of that, the change that happens in relation to oestrogen and progesterone at this stage of life is also likely to make your body less sensitive to insulin, the fat storage hormone. This is produced in response to you eating carbohydrates. When the bodys cells are less sensitive to insulin, more insulin is needed to do the same job, and more insulin produced means more fat stored.

This is where a low carbohydrate is very beneficial, focusing on low GL carbohydrates, fruit, vegetables, moderate protein and healthy fats coming from oily fish, nuts, seeds and avocados.

You may benefit from adding phytoestrogens to your diet. Phytoestrogens are plant-based chemicals (the good kind), which are structurally similar to oestrogen and exert a weak oestrogenic effect. They include soy beans, lentils, beans, chickpeas, tofu, barley, rye, oats, alfalfa, apples, pears, carrots, fennel, onion, garlic, sunflower seeds, flaxseeds, liquorice root.

Managing stress

Cortisol is one of the main stress hormones and it can lead to weight gain and leave you feeling fatigued. Even though it is the imbalance of hormones that are behind most of your symptoms, the effects of stress can be just as debilitating.

Most hormones are made from the same basic ingredients. When its under stress, the body prioritises those jobs that are useful for sustaining life, which means that when you are stressed, your body will make stress hormones ahead of anything else. So all those raw materials that might have gone to make oestrogen now wont. therefore managing your stress is essential to managing your peri-menopausal symptoms!

Exercise

As the weight creeps on, its very common for women to start getting into the types of exercise that are very punishing on the body, like running and high intensity interval training.

What do I mean by punishing?

These very intense forms of exercise stress the body and, if your body is already stressed, its just too much. Yoga, Pilates, Zumba and other dance-based classes are a good alternative as is a good power walk.

Resistance training (weights) is also good to help with the loss of muscle. Strength training also helps maintain balance, and avoid injuryimportant for protecting your skeleton both now and when youre older.

Always consult your doctor before starting a new exercise, especially if you have any underlying health conditions, you consider yourself to be unfit or very overweight.

Supplements

Menopause supplements can provide natural support for those who may be experiencing some of the symptoms related to the menopause. Its important to note that not all supplements will suit everyone and may not be safe for someone with an underlying health condition or those taking medication, therefore it is advisable to only take a supplement protocol recommended to you by a professional.

If you are struggling with managing your symptoms of menopause or maybe you would like to get your diet right before to hit that time of your life, why not schedule in an appointment with The Nutri Coach! There is no time like the present My clinic is back open and I am taking bookings for new and existing clients, so just pop me a message if you would like to schedule an appointment. contact details below.

Debbie Devane from The Nutri Coach is a qualified Nutritional Therapist and health & lifestyle coach, Debbie runs her clinic from the Glenard Clinic in Mountmellick and also offers one to one and group online consultations. Debbie is also Nutritionist to the Offaly GAA senior footballers. For more information or to make an appointment email Debbie at

info@thenutricoach.ie

Ph: 086-1720055

Facebook: The Nutri Coach @debbiedevanethenutricoach

Instagram: the_nutricoach

For more information go to http://www.thenutricoach.ie

Excerpt from:
Healthy Living: What you need to know about the Menopause - Longford Leader

US coronavirus data will now go straight to the White House. Here’s what this means for the world – Stuff.co.nz

Posted on July 19, 2020 by Prof Baldwin

OPINION: Led by physicians, scientists and epidemiologists, the US Centres for Disease Control and Prevention (CDC) is one of the most reliable sources of knowledge during disease outbreaks. But now, with the world in desperate need of authoritative information, one of the foremost agencies for fighting infectious disease has gone conspicuously silent.

For the first time since 1946, when the CDC came to life in a cramped Atlanta office to fight malaria, the agency is not at the front line of a public health emergency.

On April 22, CDC director Robert Redfield stood at the White House briefing room lectern and conceded that the coronavirus pandemic had overwhelmed the United States.

Following Redfield at the podium, President Donald Trump said the CDC director had been totally misquoted in his warning that Covid-19 would continue to pose serious difficulties as the US moved into its winter flu season in late 2020.

READ MORE:* Coronavirus: Trump cites TV host on pandemic while questioning doctors and their expertise* Coronavirus: Dire warning of 'suffering and death' as Donald Trump urges US to reopen* Coronavirus: New York City death toll may be off by thousands

Invited to clarify, Redfield confirmed he had been quoted correctly in giving his opinion that there were potentially difficult and complicated times ahead.

Trump tried a different tack. You may not even have corona coming back, the president said, once again contradicting the career virologist. Just so you understand.

The exchange was interpreted by some pundits as confirmation that the CDCs venerated expertise had been sidelined as the coronavirus continued to ravage the US.

In the latest development, the New York Times reported this week the CDC has even been bypassed in its data collection, with the Trump administration ordering hospitals to send Covid-19 data directly to the White House.

Evan Vucci

President Donald Trump speaks during a news conference in the Rose Garden of the White House in Washington.

When facing previous public health emergencies the CDC was a hive of activity, holding regular press briefings and developing guidance that was followed by governments around the world. But during the greatest public health emergency in a century, it appears the CDC has been almost entirely erased by the White House as the public face of the COVID-19 pandemic response.

This diminished role is obvious to former leaders of the CDC, who say their scientific advice has never before been politicised to this extent.

As the Covid-19 crisis was unfolding, several CDC officials issued warnings, only to promptly disappear from public view. Nancy Messonnier, director of the CDCs National Centre for Immunisation and Respiratory Diseases, predicted on February 25 that the virus was not contained and would grow into a pandemic.

The stock market plunged and Messonnier was removed from future White House press briefings. Between March 9 and June 12 there was no CDC presence at White House press briefings on Covid-19.

The CDC has erred during the pandemic, most significantly in its initial efforts to develop a test for Covid-19. The testing kits proved to be faulty a problem compounded by sluggish efforts to rectify the situation and then by severe delays in distributing enough tests to the public.

But many public health specialists are nevertheless baffled by the CDCs low profile as the pandemic continues to sweep the globe.

They have been sidelined, said Howard Koh, former US assistant secretary for health. We need their scientific leadership right now.

Manuel Balce Ceneta

Director of the Centers for Disease Control and Prevention Robert Redfield, speaks during a White House Coronavirus Task Force briefing at the Department of Education July 8, 2020, in Washington.

The CDC being bypassed in the collection of Covid-19 data is another body blow to the agencys standing.

Hospitals have instead been ordered to send all Covid-19 patient information to a central database in Washington DC.

This will have a range of likely knock-on effects. For starters, the new database will not be available to the public, prompting inevitable questions over the accuracy and transparency of data which will now be interpreted and shared by the White House.

The Department of Health and Human Services, which issued the new order, says the change will help the White Houses coronavirus task force allocate resources. But epidemiologists and public health experts around the world fear the new system will make it harder for people outside the White House to track the pandemic or access information.

This affects all nations, because one of the CDCs roles is to provide sound, independent public health guidance on issues such as infectious diseases, healthy living, travel health, emergency and disaster preparedness, and drug efficacy. Other jurisdictions can then adapt this information to their local context expertise that has become even more essential during a pandemic, when uncertainty is the norm.

It is difficult to recall a previous public health emergency when political pressure led to a change in the interpretation of scientific evidence.

Sarah Silbiger

Dr. Robert Redfield, director of the Centres for Disease Control and Prevention, left, listens during a House Committee on Energy and Commerce on the Trump administration's response to the Covid-19 pandemic on Capitol Hill in Washington.

Despite the inevitable challenges that come with tackling a pandemic in real time, the CDC remains the best-positioned agency not just in the US but the entire world to help us manage this crisis as safely as possible.

In the absence of US leadership, nations should start thinking about developing their own national centres for disease control. In Australias case, these discussions have been ongoing since the 1990s, stymied by cost and lack of political will.

Covid-19, and the current sidelining of the CDC, may be the impetus needed to finally dust off those plans and make them a reality.

Erin Smith is anAssociate Professor in Disaster and Emergency Response at theSchool of Medical and Health Sciences atEdith Cowan University.

This article is republished from The Conversation under a Creative Commons license. Read the original article.

Read the rest here:
US coronavirus data will now go straight to the White House. Here's what this means for the world - Stuff.co.nz

Calm and chill: What are the benefits of CBD Oil? – mtltimes.ca

Posted on July 19, 2020 by Prof Baldwin

In 2018, the global CBD industry reached a market value of 4.6 billion dollars. This number is expected to grow by 22%by 2025. Hence the question, what are the benefits of CBD Oil? With all the benefits CBD may have, the hype comes as no surprise.

If youve ever experienced anxiety, chronic pain, insomnia, or skin issues, youve likely heard of CBD as a form of alternative medicine. However, you may be asking yourself, What are the benefits of CBD oil?

Weve narrowed down the top CBD oil benefits and all you need to know about this popular natural remedy.

What Is CBD Oil?

Before we dive into the wonderful benefits of CBD oil, its important for new users to know exactly what it is.

CBD, or cannabidiol, is one of many compounds found in the Cannabis sativa plant. Often confused with marijuana, CBD has no psychoactive effects.

Extracted from the leafy, lush cannabis plant, CBD oil is diluted with a carrier oil like hemp seed oil or grapeseed oil. These carrier oils make it easier for your body to absorb CBD.

With the legalization of cannabis in many states, the CBD industry has gained major popularity. CBD has become a popular form of alternative medicine for many. Here are the top medical benefits of CBD oil.

What Are the Benefits of CBD Oil?

1. Anxiety & Depression Relief

According to the Anxiety and Depression Association of America,depression and anxiety disorders are both in the top 10 leading causes of disability worldwide. Many who suffer from these mental disorders turn to CBD oil for natural relief.

While pharmaceutical drugs may be expensive and can come with severe side effects, this makes the appeal of CBD oil that much greater. One of CBDs main abilities is to enhance serotonin levels in the brain. This can help increase mood and sociability.

One study also found that CBD oil can have a more rapid and long-lasting antidepressant effect than other pharmaceuticals.

2. Pain Relief

One of the most common uses for CBD oil is pain relief. For those that sufferfrom chronic pain or arthritis, CBD oil as a topical solution can be a life-changer.

CBD oil works toreact with receptors in both your brain and the immune system. CBD is said to attach itself to your bodys receptors to help your cells respond to pain. Many use CBD oil for common arthritis and chronic pains in the muscles and joints.

3. Inflammation Relief

For those with acne and other skin conditions, CBD oil is a popular natural inflammatory.

Some studies found that CBD oil can provide relief for acne, eczema, itchiness, and even skin cancer. CBD oil is also very hydrating, which can help with anti-aging. Because of its moisturizing properties, CBD oil is a common ingredient found in many skin care products.

Benefits of Smoking & Vaping CBD Oil

While there are many ways to ingest CBD oil, smoking and vaping are two of the most popular.

One of the greatest benefits of smokingCBD is that it gets delivered to your lungs at a rapid pace. This allows for near-immediate heightened benefits.

For those who use a vape pen, one of the best benefits of vaping CBD is that its simple and convenient on the go. If youre looking for an easy way to try CBD oil, consider smoking or vaping.

Try CBD Oil Today

While CBD is by no means a cure-all, those looking fornatural relief may find it with CBD oil. Now that youve answered the question, what are the benefits of CBD oil?,are you ready to try it for yourself?

For more helpful articles, browse our website.

Other interesting articles from mtltimes.ca and totimes.ca

Like Loading...

Link:
Calm and chill: What are the benefits of CBD Oil? - mtltimes.ca

IMA Official Says India’s Indigenous COVID-19 Vaccine to Reach Usable Stage Only After 2020 – The Weather Channel

Posted on July 19, 2020 by Prof Baldwin

Multiple Indian COVID-19 vaccines set to enter trial stages.

While India is set to begin the trials of its indigenous coronavirus vaccine from this week, a top official from the Indian Medical Association (IMA) has claimed that a vaccine cure for the deadly COVID-19 upon its development and marketing would reach usable stage only after 2020.

"A usable vaccine to cure COVID-19 and bringing the same to good use would go beyond 2020. Developing a vaccine for viral infections is a longer process as firstly, these infections have shorter immunity and secondly, viruses mutate faster, so this makes developers clueless as to which mutation is there in which part of the country," said Dr V K Monga, IMA Board of Hospitals Chairman.

Dr Monga further added that for developing a vaccine there are multiple stages and steps. "Developing a vaccine is not a political decision, it involves a lot of steps and procedures," he said. Explaining the process, he said, "First, we isolate the virus then you develop an antidote to that, followed by animal testing and then on human volunteers. Secondly, you see the efficacy, toxicity and then its longevity as to how long it sustains."

"Since the viral infections have shorter immunity, a vaccine with a longer effect is to be seen; secondly, we have to see that it has no side effect and thirdly, viruses mutate faster and hence, it has to be seen that the vaccine is effective on most of the mutants as we don't know which mutated virus is present in which part of the country," he said.

Speaking about the rise in the recovery rate, Dr Monga said that in this particular disease, approximately 80 per cent of the people are recovering on their own. "These patients will automatically recover. Home isolation is a good thing," he said adding that people using masks and adhering to social distancing norms is also increasing recovery. However, he clarified that plasma therapy, which is being seen as the only solution to COVID-19 in place of the absence of the vaccine, can't minimise the need of a vaccine.

"In the case of COVID-19, only vaccine or immunity can defeat the present disease," he said. Regarding community spread of this virus, he added that community spread of COVID-19 has begun in India and the major causes of this are migration of labourers and discontinuing of contact tracing of COVID-19 patients.

"We have indeed moved into community transmission phase. The government may not acknowledge it but look around how the people are getting infected. There are elderly who have not stepped out of home since months yet they have contracted the infection. There are women who have only gone out to buy vegetables in a week and carried home the COVID-19 infection," he said.

"The authorities are unable to track and trace the contacts of each positive case. Also, it is believed that 80 per cent of the population is asymptomatic and have not tested themselves. A few days ago, Kerala government admitted about community transmission in a few districts despite the state having fewer cases in comparison to Delhi and Maharashtra," he added.

With 38,902 new cases reported in the past 24 hours, India's total coronavirus cases on Sunday reached 10,77,618. With 543 new deaths the death toll stood at 26,816, Health Ministry data said. Karnataka is the new hotspot state nearing 60,000 cases, as Maharashtra remained the worst-hit state, with 3,00,937 cases and 11,596 casualties. It crossed the 3-lakh mark on Saturday with Mumbai reporting over 1 lakh coronavirus cases so far.

It is followed by Tamil Nadu with total 1,65,714 cases and 2,403 deaths. The national capital, on the other hand is projecting an uplifting trend. For 17 of the last 20 days, including 11 in a row now, the number of people recovering from COVID-19 in Delhi has remained higher than newly detected infections -- no other state has come close to such a trend.

See original here:
IMA Official Says India's Indigenous COVID-19 Vaccine to Reach Usable Stage Only After 2020 - The Weather Channel

Meet Moss, the detection dog helping Tassie devils find love – The Conversation AU

Posted on July 19, 2020 by Prof Baldwin

Moss is a detection dog in training. Unlike other detection dogs, who might sniff out drugs or explosives, hell be finding some of Victorias smallest, best camouflaged and most elusive animals.

Read more: Sit! Seek! Fly! Scientists train dogs to sniff out endangered insects

These dogs use their exceptional olfactory senses to locate everything from koalas high in the trees, desert tortoises burrowed deep under soil and even whales often more effectively than any human team could aspire to.

What makes Moss unique, however, is hell not only find endangered species in the wild, but will also be part of a larger team helping endangered species breed in captivity. These dogs will be the first in the world to do this, starting with a ground-breaking trial with Tasmanian devils.

Wildlife detection dogs are a very rare type of dog they are highly motivated, engaged and energetic, but also incredibly reliable and safe around the smallest of creatures.

And Moss is the first dog to join Zoos Victorias Detection Dog squad, a permanent group of highly trained dogs that will live at Healesville Sanctuary.

Read more: Is your dog happy? Ten common misconceptions about dog behaviour

Moss was adopted at 14 months old, after he somewhat failed at being a family pet. He is a hurricane of energy with an intelligent and playful mind. Hes thriving with a job to keep him occupied and new challenges for his busy brain.

One sign he was perfect for this program was his indifference to the free range chickens at his foster home. For obvious reasons, a dog who likes chasing chickens wouldnt be a good candidate for protecting some of Australias rarest feathered treasures.

Currently Moss is learning crucial foundational skills, and getting plenty of exposure to different environments. Equally important, he is developing a deep bond and trust with his handlers.

The detection dog-handler bond is crucial not only for his happiness, but also for working success and longevity. Research from 2018 found a strong bond between a handler and their dog dramatically improved the dogs detection results and reduced signs of stress.

Healesville Sanctuary breeds endangered Tasmanian Devils every year as part of an insurance program to support conservation and research. This program is crucial to help protect the devil following an estimated 80% decline in the wild due to a horrific transmissible cancer, Devil Facial Tumour Disease.

Read more: We developed tools to study cancer in Tasmanian devils. They could help fight disease in humans

But managing a predator thats shy, nocturnal and prefers to be left alone can be tricky.

Wildlife, including Tasmanian devils, need a hands-off approach where possible, so they can maintain natural behaviours and thrive in their environment.

In the wild, devils leave scats (faeces) at communal latrine sites and use scent for communication. Male devils can tell a female is ready to mate by smelling her scat. And we think dogs could be trained to detect this, too.

Read more: Koala-detecting dogs sniff out flaws in Australia's threatened species protection

The project will also explore whether dogs can detect pregnancy and lactation in the devils.

Currently, the best way to determine if a female has young is to look in her pouch, but our preference is to remain at a distance during this important time while females settle into being new mums.

The results from this devil breeding research could offer innovative new options for endangered species breeding programs around the world.

Wildlife detection in the field means we can more accurately monitor some of our most critically endangered species, and quickly assess the impact of catastrophic events such as bushfires.

Read more: Curious kids: How far away can dogs smell and hear?

Detection dogs are the perfect intermediary between people and wildlife they can sniff out what we cant and communicate with us as a team.

Dogs may yet go from being mans best friend to the devils best friend and beyond, all starting with a happy labrador named Moss.

This article is co-authored by Naomi Hodgens, Wildlife Detection Dog Officer at Zoos Victoria, and Dr Kim Miller, Life Sciences Manager, Conservation and Research, at Healesville Sanctuary, Zoos Victoria.

The rest is here:
Meet Moss, the detection dog helping Tassie devils find love - The Conversation AU

Delivering the power of nanomedicine to patients today – DocWire News

Posted on July 19, 2020 by Prof Baldwin

This article was originally published here

J Control Release. 2020 Jul 15:S0168-3659(20)30382-5. doi: 10.1016/j.jconrel.2020.07.007. Online ahead of print.

ABSTRACT

The situation of the COVID-19 pandemic reminds us that we permanently need high-value flexible solutions to urgent clinical needs including simplified diagnostic technologies suitable for use in the field and for delivering targeted therapeutics. From our perspective nanotechnology is revealed as a vital resource for this, as a generic platform of technical solutions to tackle complex medical challenges. It is towards this perspective and focusing on nanomedicine that we take issue with Prof Parks recent editorial published in the Journal of Controlled Release. Prof. Park argued that in the last 15 years nanomedicine failed to deliver the promised innovative clinical solutions to the patients (Park, K. The beginning of the end of the nanomedicine hype. Journal of Controlled Release, 2019; 305, 221-222 [1]. We, the ETPN (European Technology Platform on Nanomedicine) [2], respectfully disagree. In fact, the more than 50 formulations currently in the market, and the recent approval of 3 key nanomedicine products (e. g. Onpattro, Hensify and Vyxeos), have demonstrated that the nanomedicine field is concretely able to design products that overcome critical barriers in conventional medicine in a unique manner, but also to deliver within the cells new drug-free therapeutic effects by using pure physical modes of action, and therefore make a difference in patients lives. Furthermore, the >400 nanomedicine formulations currently in clinical trials are expecting to bring novel clinical solutions (e.g. platforms for nucleic acid delivery), alone or in combination with other key enabling technologies to the market, including biotechnologies, microfluidics, advanced materials, biomaterials, smart systems, photonics, robotics, textiles, Big Data and ICT (information & communication technologies) more generally. However, we agree with Prof. Park that it is time to examine the sources of difficulty in clinical translation of nanomedicine and move forward . But for reaching this goal, the investments to support clinical translation of promising nanomedicine formulations should increase, not decrease. As recently encouraged by EMA in its roadmap to 2025, we should create more unity through a common knowledge hub linking academia, industry, healthcare providers and hopefully policy makers to reduce the current fragmentation of the standardization and regulatory body landscape. We should also promote a strategy of cross-technology innovation, support nanomedicine development as a high value and low-cost solution to answer unmet medical needs and help the most promising innovative projects of the field to get better and faster to the clinic. This global vision is the one that the ETPN chose to encourage for the last fifteen years. All actions should be taken with a clear clinical view in mind, without any fanfare, to focus on what matters in real life, which is the patient and his/her quality of life. This ETPN overview of achievements in nanomedicine serves to reinforce our drive towards further expanding and growing the maturity of nanomedicine for global healthcare, accelerating the pace of transformation of its great potential into tangible medical breakthroughs.

PMID:32681950 | DOI:10.1016/j.jconrel.2020.07.007

Solve Puzzles for Science | Foldit

Posted on July 19, 2020 by Prof Baldwin

(This post was originally sent out on July 3 to our mailing list. You can sign up for the mailing list here to receive weekly updates about Foldit, including tips and tricks and see the top-scoring solutions to the week's puzzles. Don't forget to join our Discord as well to stay in the chat even when you're not folding!)

Hey folders!

Dev Josh here with your weekly Foldit update.

This week we saw the introduction of the Reaction Design tool. The devs are working hard on polishing it up and making it more usable! As always, thanks for your feedback and bug reports. You can submit more feedback here.

In this puzzle, I accidentally evo'ed on a broken developer build and got the top score. Whoops, sorry about that!Here are some of the solutions at the top of the leaderboards. [A note from our scientists: the top of the leaderboards doesn't always mean the most scientifically useful. These highlights are not scientific feedback and are not officially endorsed as scientifically valid designs by the Foldit team.]

Join the mailing list to see what others are folding!

This week's recipe is an oldie but a goodie from drjr. The recipe is called Reset, and it does what it says on the tin: reset to the best score, unfreeze the protein, remove all your bands, and set the CI to 1. A simple recipe, but a handy quality of life tool for when you just need to backtrack a little.

Quick shoutout to argyrw for always being a friendly voice in chat! Say hi to her in global or veteran chat.

Beginner: Are you still using Pull to draft your protein in the early game? Try making cutpoints and moving pieces around with the Move tool, it's so much easier! Don't forget to disable cutpoint bands in the Behavior tab, or they'll all come together again when you wiggle.

Intermediate: It can be really tempting mid-game to just switch to running recipes. But give some time to carefully inspect every acceptor and donor (the red and blue dots) to see what hydrogen bonds you can form, and manually mutate as needed. Not only will this lower your BUNS, but it'll help form a strong hbond network. The scientists love this, and your rank will too!

Expert: If you haven't already, read bkoep's blog on binder design metrics. DDG, SASA, and SC are going to become really important soon since we're looking to add objectives for them. So understanding and practicing these principles now can help you get a headstart on the competition! Use the protein design sandbox to try out some ideas.

Have a tip to share or a recipe to recommend? Reply with your suggestions or make a wiki page for your ideas! Reaction Design doesn't have a page yet, so if you understand this tool, help out your community by writing about it! (Since writing this post, LociOiling has graciously created the page for Reaction Design puzzles.)

Until next time, happy folding!

See more here:
Solve Puzzles for Science | Foldit

Do you know about Andropause aka male menopause? – The Indian Express

Posted on July 19, 2020 by Prof Baldwin

By: Lifestyle Desk | New Delhi | Updated: July 19, 2020 7:19:41 pm A few of the visible common symptoms for men experiencing andropause include tiredness and fatigue. (Photo: Getty)

While there is a constant conversation around the effects of menopause and the possible symptoms, we often dont talk about the fact that men too go through a similar phase. Just like women, men too face a decrease in the level of hormone in the body between the age of 45 and 65 years.

Dr Rashmi Rai, Medical Head of Age hance Clinic says, It isnt as clearly defined as a period of menopause in women, but men naturally experience a decline in hormone levels and more particularly testosterone as they age. This phase is medically termed as Andropause and also commonly known as male menopause.

Dr Rashmi says, Andropause can create a range of symptoms that affect a mans physical, sexual, and psychological functioning also bodys immune response.

Visible symptoms include fatigue and burnout along with low physical strength. Emotionally, men tend to suffer from anxiety along with depression and mood swings. Dr Rashmi also stresses how these symptoms can be a result of existing conditions such as diabetes, high stress, poor digestive system, gut dysfunction, inflammation, alcoholism, and even smoking.

However, these symptoms usually differ from man to man because the decline in testosterone and other hormone levels depends on numerous factors. But, men commonly experience erectile dysfunction or lack of sexual desire along with a decrease in bone density levels.

It becomes important to pay close attention to changes in behaviour and physical symptoms before one can even conclude they are going through andropause. In many cases, a doctor will need to rule out underlying medical issues addressing the root cause that could be contributing to the condition while diagnosing if a man is experiencing andropause or male menopause, she adds.

Dr Rashmi shares how BHRT i.e. Body Identical hormone replacement therapy is recognised worldwide to treat andropause.

BHRT is an approach with the concept of one size fits all approach which includes personal formulations which are tailored as per individuals specific needs shares the doctor. Body identical Testosterone replacement is recommended when a mans body has lost the ability to produce enough of this hormone on its own, says Dr Rashmi.

In fact, herbs like Indian ginseng or Ashwagandha can also be used to treat andropause along with optimal nutrition, diet and correction of hormone imbalances. Dr Rashmi suggests, A diet containing optimum protein is the key. Eating good and healthy fats like Omega 3 helps build a better foundation for hormone production.

The Indian Express is now on Telegram. Click here to join our channel (@indianexpress) and stay updated with the latest headlines

For all the latest Lifestyle News, download Indian Express App.

IE Online Media Services Pvt Ltd

Read the original here:
Do you know about Andropause aka male menopause? - The Indian Express

Evolving habits – Daily Pioneer

Posted on July 19, 2020 by Prof Baldwin

People are finding ways to eliminate hospital visits, which in turn have led them to adopt healthy lifestyle choices, tele-health and frequent self monitoring. Preventive healthcare will hence gain attention in the post-COVID world, says Vikram Ahluwalia

It has been months now that the pandemic is upon us. The rising number of cases is indeed unsettling, especially when we are not even supposed to share or lend a shoulder despite the stress no warm hugs or comforting strokes. And caution is of paramount importance. For the first time ever, humanity stands physically distant and yet connected through hope.

This situation has triggered several transformations into human civilisation, which are now going to be more strongly embedded in our lifestyles. The pandemic has also exposed the vulnerabilities of our healthcare system and the crisis has offered opportunities to transform our healthcare industry. At a time when theres no cure or vaccine to the deadly virus, the pandemic has elevated the importance and acceptance of preventive healthcare. In March 2020, when the government started educating people about the preventive measures to combat COVID-19, the people responded positively to the hygiene practices. Hand-washing kiosks came up at public places in many states and the public was seen making use of it. This is remarkable for a country where only 60 per cent of houses have access to soap and water. All this shows that people are ready for preventive healthcare.

The rapid pace of social and technological changes have led to adverse lifestyle choices, resulting in deteriorating well-being among individuals. Incidences of various lifestyle diseases (co-morbidities) such as diabetes, asthma, hypertension, heart diseases and others are on the rise. However, the adage, prevention is better than cure is now well etched into the minds of consumers as they have now started treating health more seriously. The consumers have realised that most of these health risks can considerably be reduced through preventive care. We have already seen consumers adopting healthy lifestyles, eating home-cooked food, practicing sleep hygiene, opting health supplements and doing yoga and physical exercises to stay fit.

For years now preventive healthcare was by and large losing out the attention it deserved. But recently, the adoption of innovations that can reduce or eliminate hospital stays have picked up pace. The trend is leading to increasing adoption of healthy lifestyle choices, tele-health and self-monitoring via POCT devices and by going for preventive care check-ups. Like the saying goes, a stitch in time saves nine; going for preventive or diagnostic care check-ups helps in detecting diseases in early stages and identifying nutritional and other deficiencies. It helps in treating the diseases with ease and without impacting the health of the patient. Diagnostic care also helps in identifying deficiencies in the body and helps the patient adopt relevant lifestyle changes. Along with that, early diagnosis and prevention of disease and its symptoms may reduce the burden on inpatient/outpatient care, medications and rehabilitation. More people must opt for regular or annual testing and full body check-ups, and they should update themselves about whats happening inside their bodies. A preventive test is like a report card which tells an individual how he/she has performed. So while, you are taking all those supplements and lifestyle choices, its important to know how your body is reacting to it.

Today, theres also a huge focus towards immunity; the stress on boosting immunity has never been stronger. It is a known fact that individuals who are a bit low on immunity have a reduced ability to fight infections and other diseases. This may be caused by certain chronic diseases or conditions, such as anemia, heart diseases, lung diseases, AIDS, cancer, diabetes, hypertension, malnutrition, and certain genetic disorders. An infected person with such pre-existing disease(s) is known to carry co-morbidities. Patients with immune-compromised state and/or co-morbidity are vulnerable to a higher risk of life threatening infections. A methodological assessment of a patients immune status can assist both the patient and doctor to estimate his/her risk of infection, its outcome and next course of actions for the betterment.

Indeed, a body needs exercise to retain functionality and fitness. At the same time, it would need proper nutritional foundation to have good health and a strong immune system. And the only way to know whats lacking and to understand whether the diet regime is actually benefitting is to undergo relevant diagnostic testing. As India unlocks itself in phases, keeping a healthy immune system can help prevent or reduce risks of infections or diseases.

As consumers are now moving towards healthier choices, by avoiding outside food, learning which macro or micro nutrients are lacking in their bodies is the best way to replenish them. While testing is definitely going to play a critical role in delivering insights about the body, its immunity and its health, the role of doctors will always remain pivotal to the patients. Understanding and interpreting the reports correctly is a doctors forte. A doctor understands the health requirements of an individual and can appropriately consider medical history of the patient before setting the course of action for further improvement on the basis of the diagnosis made.

The diagnostic efforts to counter COVID-19 have already aroused much interest and spread awareness about preventive testing and its importance. The effort needs to educate people further so that India witnesses a shift from curative care to preventive care, from treatment to health and well being.

Just like airbags in the car is a preventive step to prevent a larger damage that can cost life, preventive care and check-ups should be imperative for citizens and ways and means need to be devised to make it accessible for one and all. Only with a preventive mindset can we look at a country which spends lesser on health because its people are by and large leading a healthy life.

(The writer is the Director-Marketing, SRL Diagnostics.)

Read the rest here:
Evolving habits - Daily Pioneer

Healthcare Nanotechnology (Nanomedicine) Market Forecasted To Surpass The Value Of US$ XX Mn/Bn By 2015 2021 – Jewish Life News

Posted on July 19, 2020 by Prof Baldwin

Insights on the Global Healthcare Nanotechnology (Nanomedicine) Market

PMR is one of the leading market research companies in India. Our team of research analysts have a deep understanding and knowledge related to the latest market research techniques and use their analytical skills to curate insightful and high-quality market reports. The presented data is collected from credible primary sources including marketing heads, sales managers, product managers, industry experts, and more.

As per the report, the global Healthcare Nanotechnology (Nanomedicine) market reached a value of ~US$ XX in 2018 and is likely to surpass a market value of ~US$XX by the end of 2029. Further, the report reveals that the Healthcare Nanotechnology (Nanomedicine) market is set to grow at a CAGR of ~XX% during the forecast period (2019-2029)

Request Sample Report @ https://www.persistencemarketresearch.co/samples/6370

Critical doubts related to the Healthcare Nanotechnology (Nanomedicine) market addressed in the report:

Request Report Methodology @ https://www.persistencemarketresearch.co/methodology/6370

Segmentation of the Healthcare Nanotechnology (Nanomedicine) market

The report bifurcates the Healthcare Nanotechnology (Nanomedicine) market into different segments to provide a clear understanding of the various aspects of the market.

Regional Outlook

The regional outlook section of the report includes vital data such as the current trends, regulatory framework, The Healthcare Nanotechnology (Nanomedicine) market study offers critical data including, the sales volume, sales growth, and pricing analysis of the different products in the Healthcare Nanotechnology (Nanomedicine) market.

Key players in the global nanomedicine market include: Abbott Laboratories, CombiMatrix Corporation, GE Healthcare, Sigma-Tau Pharmaceuticals, Inc., Johnson & Johnson, Mallinckrodt plc, Merck & Company, Inc., Nanosphere, Inc., Pfizer, Inc., Celgene Corporation, Teva Pharmaceutical Industries Ltd., and UCB (Union chimique belge) S.A.

Key geographies evaluated in this report are:

Key features of this report

For any queries get in touch with Industry Expert @ https://www.persistencemarketresearch.co/ask-an-expert/6370

Important insights present in the report:

See more here:
Healthcare Nanotechnology (Nanomedicine) Market Forecasted To Surpass The Value Of US$ XX Mn/Bn By 2015 2021 - Jewish Life News

Northern youth group seeks speedy passage of Bill to establish National Innovation agency – Daily Sun

Posted on July 19, 2020 by Prof Baldwin

Sola Ojo, Kaduna

The leadership of Arewa Youth Assembly on Sunday appealed to the leadership of the 9th National Assembly to give speedy passage of the bill to establish a National Innovation Agency (NiNNOVA Establishment Bill 2020) which has already scaled through the first reading early July.

The bill, sponsored by the lawmaker representing Nnewi North/South/Ekwusigo Federal Constituency, Chris Emeka Azubogu, is expected to play a leading role in the development of Nigerias innovation ecosystem by coordinating, networking, fostering, and partnering different organizations from various fields such as academia, technology, industry, finance and investment.

The group in a statement through its Speaker, Mohammed salihu Danlami noted that, the main focus of the agency if established, would be on utilizing knowledge management to achieve innovation, which could be employed as the principal tool in improving quality of life and as a driving tool for an increasingly competitive economy.

According to Mohammed, NiNNOVA would undertake a broad-based and systematic approach in facilitating innovation development in Nigeria, both in terms of making improvements and pioneering new initiatives.

More precisely, NiNNOVA will focus on fostering strategic innovation and industry innovation, which will enhance national productivity, encourage economic restructuring and social development as well as promote national competitiveness by focusing on coordinating industrial clusters both at the policy and operational levels, promoting innovation culture and building up innovation systems, with a broader aim to transform Nigeria into an innovation-driven economy.

The National innovation Agency, if enacted, will coordinate innovation activities as well as administer funding to grow and support the innovation ecosystem and entrepreneurship in Nigeria. It shall exist to promote the development of efficient and innovative Nigerian systems within thematic areas such as technology, ICT, nanomedicine, nanotechnology, agriculture, agribusiness, biotechnology, health, education etc, he added..He continued, this is what Nigeria lacks but so desperately needs at the moment so that we can have a knowledge-based economy, commodity-based economy such as the one we currently operate does not get any country anywhere in terms of national development.

To buttress his point of view on the bill Mohammed sited example of South Korea, which developed an innovation-based economy and is not up to the size of a state in the Soviet Union, has about the economic size of the Soviet Union. China, Japan and India which are global economic giants do not have a drop of oil. India for instance rakes in a whopping 140 billion USD annually from ICT-based solutions and services.

This is just an inkling of what can be achieved through innovation. The Swedish Innovation Agency champions and coordinates innovation-based activities in Sweden for national development. The Thailand Innovation Agency plays a similar role in Thailand. The list is endless; virtually every country in the world has an Agency whose mandate is the coordination of innovation for national development.

In view of the crucial and critical role the National Innovation Agency will play in re-tooling our national economy for national development, we therefore urge the Honourable Speaker of the House of Representatives Rt. Hon Femi Gbajabiamila to please call for the second reading of this Bill and to expedite action for its eventual passage as such an agency will add huge value to Nigeria in terms of wealth creation and overall national competitiveness and development, the group added.

";n.innerHTML="window._taboola = window._taboola || [];_taboola.push({mode:'thumbnails-c', container:'taboola-below-article', placement:'below-article', target_type: 'mix'});window._taboola = window._taboola || [];_taboola.push({mode:'thumbnails-d', container:'taboola-below-article-second', placement:'below-article-2nd', target_type: 'mix'});";insertAfter(t,e);insertAfter(n,t)}injectWidgetByMarker('tbmarker');

Follow this link:
Northern youth group seeks speedy passage of Bill to establish National Innovation agency - Daily Sun

CLR 131 Leads a New Generation of Lipid-Based Cancer Drug Delivery Systems – OncLive

Posted on July 19, 2020 by Prof Baldwin

A novel compound that uses abundant lipids in cancer cell membranes to deliver a radioisotope to the tumor environment shows early signs of efficacy in a range of B-cell malignancies, including multiple myeloma.1,2

CLR 131 is a phospholipid-drug conjugate (PDC) designed to provide a payload of iodine-131 directly to the cytosol and cytoplasm of tumor cells.3 Cellectar Biosciences, a biopharmaceutical company based in Florham Park, New Jersey, is investigating the potential of CLR 131 in hematologic and solid tumors. The company also is exploring its PDC approach as a platform technology for other oncologic conjugates.4

Positive clinical trial data have been announced for patients with B-cell malignancies, 2 including multiple myeloma, and CLR 131 has secured fast track designation from the FDA for 3 separate indications.5-7 If it lives up to its potential, CLR 131 could be the first of many such drugs from Cellectar, with other payloads being explored.1

Meanwhile, the underlying technology shines a light on the broader use of lipids as vehicles for cancer therapies. With the advent of nanotechnology in medicine, lipid-based carriers have been designed to encapsulate drugs to improve delivery to the tumor site, in the hopes of reducing generalized toxicity and improving therapeutic effect.8-10

Several FDA-approved liposomal formulations of common chemotherapy drugs are on the market.11 Ongoing clinical efforts aim to improve the efficacy of some of these drugs; notably, daunorubicin plus cytarabine (CPX-351; Vyxeos)12 and liposomal irinotecan (Onivyde).13 CPX-351 was initially approved in 2017 in acute myeloid leukemia settings and Onivyde was cleared in 2015 for progressive metastatic pancreatic adenocarcinoma.

Additionally, newer lipid-based strategies aimed at overcoming the challenges of liposomal formulations are in development. These include SB05-EndoTAG-1 (SynCore Biotechnology), which combines paclitaxel with lipids14; mRNA-2416 (Moderna), which encodes OX40L in a lipid nanoparticle15; and Promitil (LipoMedix), a lipid-based form of mitomycin-C.16

Investigators have long sought more specific cancer drugs with reduced off-target toxicity and enhanced therapeutic efficacy. The development of molecularly targeted therapies has been one result, but new drug delivery systems may achieve similar goals. Thanks to the advent of nanotechnology, significant advances in the development of drug carrier technologies for cancer therapy have occurred in the past several decades.8-10

Broadly speaking, drug carriers are designed to shield drugs from interaction with healthy cells and facilitate accumulation at the tumor site. The latter is believed to occur as a result of the enhanced permeability and retention effect. Nanoparticles are too big to readily pass through the normal vasculature into healthy tissues but not the abnormal, leaky blood vessels characteristic of the tumor microenvironment. The lack of lymphatic drainage from tumor vessels adds to this effect.17

Nanoparticles prepared from natural polymers, such as lipids, proteins, and peptides, represent the most promising approach. In particular, liposomes are the most extensively studied type of nanoparticle drug carrier and account for first generation of FDA-approved lipidbased drug delivery systems.18

Liposomes are spherical vesicles composed of 1 or more phospholipid bilayers surrounding an aqueous core. Depending on its properties, a drug can be encapsulated within the core (a hydrophilic drug) or held in the bilayer (a hydrophobic drug) (Figure 1).8,11

Among their advantages over naked drugs, liposomes and other lipid-based delivery systems can reduce toxicity, prolong half-life in the circulation, and improve pharmacokinetics. Additionally, because of their biocompatibility with cell membranes, they are more readily taken up into cells via endocytosis. Because the drug remains behind a lipid barrier once inside the cell, being released only upon lysosomal degradation, it may avoid eviction from the cell by transporter pumps that play a large role in drug resistance.9,11,19

Chemotherapy Delivery

Beginning with the 1995 approval of doxorubicin hydrochloride liposome injection (Doxil) for the treatment of AIDS-related Kaposi sarcoma and, subsequently, multiple myeloma and ovarian cancer, severalliposomal formulations of conventional chemotherapies have become available.9,11

Despite better developed drug properties, some approved liposomal formulations only moderately improved patient survival compared with conventional chemotherapy.11 Their development revealed a number of inherent challenges. Early on, investigators discovered that liposomes were rapidly recognized and engulfed by macrophages, which led to their destruction by the mononuclear phagocyte system.10,20

Nevertheless, ongoing clinical development has demonstrated greater efficacy for several of these compounds. CPX-351 continued to show an overall survival (OS) benefit versus conventional 7 + 3 chemotherapy for patients with newly diagnosed high-risk/secondary acute myeloid leukemia in findings from a phase 3 trial (NCT01696084) presented at the 2020 European Hematology Association Virtual Congress.12

After a median follow-up of 60.65 months, the median OS was 9.33 months (95% CI, 6.37-11.86) and 5.95 months with CPX-351 and 7 + 3, respectively (HR, 0.70; 95% CI, 0.55-0.91). The estimated 3- and 5-year OS rates were also higher with CPX-351 versus 7 + 3, at 21% versus 9% and 18% versus 8%, respectively.12

The combination of Onivyde plus fluorouracil, leucovorin, and oxaliplatin (NALIRIFOX) demonstrated promising outcomes as a frontline treatment for patients with locally advanced or metastatic pancreatic ductal adenocarcinoma. Findings from a phase 1/2 study (NCT02551991) for 32 patients were presented at the European Society of Medical Oncology (ESMO) World Congress on Gastrointestinal Cancer 2020. The NALIRIFOX regimen resulted in a median progression-free survival of 9.2 months (95% CI, 7.69-11.96) and a median OS of 12.6 months (95% CI, 8.74-18.69). The overall response was 34.4% (95% CI, 18.6%-53.2%), consisting of 1 complete response (CR) and 10 partial responses (PRs).13

An international, randomized phase 3 trial (NAPOLI 3; NCT04083235) exploring the use of frontline NALIRIFOX compared with gemcitabine and nab-paclitaxel (Abraxane) in patients with metastatic pancreatic cancer is now under way.

Other Payloads

Besides chemotherapy, other cancer drugs can be contained within liposomes. Nucleic acidbased drugs, which include oligodeoxynucleotides, plasmid DNA, short interfering RNA, and messenger RNA (mRNA), can be used for gene therapy. However, the use of naked genetic material is challenging due to its large size, instability in the circulation, and susceptibility to degradation by nucleases. Lipid-based carriers offer a way to address these issues.20,21

Bio-Path Holdings is developing prexigebersen (BP1001), BP1002, and BP1003; the latter is still in preclinical testing. All 3 are liposome-encapsulated antisense oligonucleotides that inhibit synthesis of the GRB2, BCL2, and STAT3 proteins, respectively.22-24 Prexigebersen is most advanced in clinical development; Bio-Path recently announced an updated interim analysis of stage 1 of an ongoing phase 2 study in AML (NCT02781883).

Among 17 evaluable patients treated with a combination of prexigebersen and low-dose cytarabine (LDAC), 11 had a response, including 5 CRs.25 Moving forward, patients in stage 2 of the trial will be treated with a combination of prexigebersen, decitabine, and venetoclax, instead of LDAC, following initial safety testing of this combination in which 3 of 6 patients had a response.26

All the currently approved liposomal formulations rely on passive targeting of the tumor tissue through enhanced permeability and retention.9 However, the irregular tumor vasculature thought to be responsible for this effect can also work against effective drug delivery, as can the elevated fluid pressure surrounding the tumor.10,11

To further enhance active tumor-targeted drug delivery, development of functionalized liposomes has also been explored, in which properties of the liposome are engineered for improvements. This includes altering the type of lipid to affect the size or charge of the liposome or conjugating other drugs to the liposome surface. Immunoliposomes, for example, are generated by chemically coupling liposomes with antibodies or antibody fragments against cancer cellspecific antigens, such as EGFR.9,11,18,19

SB05-EndoTAG-1 encapsulates paclitaxel in positively charged liposomes. These are designed to interact with the negatively charged endothelial cells of newly formed blood vessels, releasing paclitaxel into these cells, killing them, and cutting off the tumors blood supply.14 Phase 3 trials are ongoing in locally advanced/metastatic pancreatic cancer (NCT03126435) and triple-negative breast cancer (NCT03002103).

Other types of lipid-based drug deliverysystems, beyond lyposomes, come with advantages and disadvantages. There are several major types of lipid nanoparticles; the lipid core may be solid, liquid, or both, and the core may contain single or multiple compartments of drug, among other distinctive features.8,19

Moderna Therapeutics is developing 2 lipid nanoparticle-based encapsulation systems that contain synthetic mRNAs encoding immunostimulatory proteins.27 Results from an ongoing study of mRNA-2416 (NCT03323398), in which the encapsulated mRNA encodes OX40L, were presented at the 2020 American Association for Cancer Research Virtual Meeting I. Despite being well tolerated, mRNA-2416 had modest antitumor activity, but it is hoped that this may be enhanced by combining it with durvalumab (Imfinzi), a PD-L1 inhibitor. This combination is being evaluated in part B of the study.15

Lipid-drug conjugates (LDCs), in which cancer drugs are linked with lipid molecules, are among the most promising types of lipid nanoparticle. LDCs also can facilitate the loading of hydrophobic drugs into other lipid-based carrier systems.8,28

Promitil is an LDC involving mitomycin-C that is further encapsulated in a pegylated liposomal carrier.16 In a phase 1a doseescalation study, toxicity was lower and dose tolerability higher than historical data for naked mitomycin-C. In the phase 1b portion of the trial in patients with advanced, chemorefractory colorectal cancer, Promitil was evaluated alone or combined with either capecitabine or capecitabine and bevacizumab (NCT01705002).

Among 36 response-evaluable patients, stable disease was observed in 42% at week 12. Median survival was 8.7 months, and adding capecitabine and bevacizumab to Promitil had no further effect. AEs were mostly mild to moderately severe.29

Cellectar Biosciences is developing a different kind of LDC. CLR 131 is a PDC, a proprietary mix of phospholipid ethers (PLEs) covalently linked to a cytotoxic radioactive isotope of iodine-131.3

PDCs offer a lipid-based carrier system with a unique feature: They exploit the altered lipid composition of cancer cell membranes to more actively target tumors. PLEs are naturally occurring lipids that are taken up into cells via lipid rafts, cholesterol-rich regions of the plasma membrane that play a key role in cell signaling. PLEs accumulate in cancer cells, in part because their cell membranes contain an enhanced number of lipid rafts.1,30-32

Thus, the lipid rafts on the surface of cancer cells are bound by multiple PDCs via their PLE moiety. When the lipid rafts eventually undergo transmembrane flipping, they deliver the PLEs and their radioactive payload into the cancer cell. Proposed advantages of this system include the PDCs ability to gain entry into a wide variety of cancer types and indiscriminately target all cells within a tumor without relying on expression of a specific antigen.1

Furthermore, the technology could offer considerable flexibility in the types of payloads that can be used and could be further refined via linker design (Figure 2).1 Cellectar has several other PDCs in preclinical development, including agents designed to produce cell cycle arrest, inhibit protein translation, and disrupt the cytoskeleton.33

CLR 131 has been granted orphan drug status in multiple myeloma, Ewing sarcoma, neuroblastoma, osteosarcoma, rhabdomyosarcoma, and lymphoplasmacytic lymphoma (LPL).34 CLR 131 also has fast track designation for multiple myeloma, diffuse large B-cell lymphoma (DLBCL), and LPL/Waldenstr.m macroglobulinemia (WM).5-7

The most recent fast track designation, for LPL/WM, follows positive results from the ongoing phase 2 CLOVER-1 trial (NCT02952508); Cellectar announced that all 4 treated participants with LPL/WM so far achieved an objective response, with 1 achieving CR.2,7,34

In this trial, patients with relapsed/refractory (R/R) B-cell lymphomas, multiple myeloma, and non-Hodgkin lymphoma (NHL) were treated with 3 doses of CLR 131: less than 50 mCi total body dose (TBD; an intentionally subtherapeutic dose), 50 mCi TBD, and 75 mCi TBD. Patients in both the multiple myeloma and NHL cohorts had a median age of 70 years and were heavily pretreated.34

The overall response rate (ORR) for patients with multiple myeloma (n = 33) was 34.5% across all doses (42.8% at the 75 mCi dose; 26.3%, 50 mCi). In patients with NHL, the ORR among 19 patients was 42% (43%, 75 mCi; 42%, 50 mCi). Subtype assessments demonstrated ORRs of 30% (with 1 CR) in patients with DLBCL and 33% for patients with chronic lymphocytic leukemia, small lymphocytic leukemia, and marginal zone lymphoma. CLR 131 was well tolerated across all dose groups.34

Cellectar simultaneously announced the completion of a phase 1 dose-escalation study of CLR 131 in patients with R/R multiple myeloma (NCT02278315). In this trial, 4 single-dose cohorts were examined (25, 37.5, 50, and 62.5 mCi TBD). The study was modified in 2018 to test fractionated doses (2 doses of 31, 37.5, or 40 mCi TBD, given 1 week apart). For both the single- and fractionated-dose cohorts, CLR 131 was administered as 30-minute intravenous infusions in combination with 40-mg weekly low-dose dexamethasone.34

All patients (n = 17) enrolled in the single-dose cohorts experienced clinical benefit, with 16 participants achieving stable disease. Pooled median OS from the 4 cohorts was 22 months.

Compared with patients administered the highest single dose of CLR 131, the cohort that received the lowest fractionated dose showed better tolerability and safety; despite receiving an 18% higher dose overall, these patients required less supportive care (such as blood transfusions) and had a 50% greater reduction in M protein levels, a surrogate marker of efficacy.34

The next fractionated-dose cohort, which received a total 75 mCi TBD (2 ~ 37.5 mCi TBD; n = 4), had a 50% PR rate, defined as at least a 50% decrease in M protein from baseline. The remaining 2 patients experienced a minimal response, defined as an M protein decrease between 25% and 49.9%.

The authors concluded that CLR 131 showed a clear dose response, with higher doses producing greater efficacy without unacceptable toxicity.35

1. A proprietary platform that specifically delivers oncologic warheads to tumor cells. Cellectar Biosciences. Accessed June 1, 2020. https://www.cellectar.com/technology

2. Cellectar Biosciences announces CLR 131 achieves primary efficacy endpoints from its phase 2 CLOVER-1 study in relapsed/refractory B-cell lymphomas and completion of the phase 1 relapsed/refractory multiple myeloma dose escalation study. News release. Cellectar Biosciences. February 19, 2020. Accessed June 1, 2020. bit.ly/2NZUflr

3. Longcor J, Oliver K, Friend J, Callandar N. Interim evaluation of a targeted radiotherapeutic, CLR 131, in relapsed/refractory diffuse large b cell lymphoma patients (R/R DLBCL). Presented at: 2019 European Society for Medical Oncology Congress; Barcelona, Spain; September 27-October 1, 2019. Abstract 5797. bit.ly/2VMpSDc

4. CLR 131. Cellectar Biosciences. Accessed May 25, 2020. http://www.cellectar.com/product-pipeline/clr-131

5. Cellectar receives FDA fast track designation for CLR 131 in relapsed or refractory multiple myeloma. News release. Cellectar Biosciences, Inc. May 13, 2020. Accessed May 25, 2020. https://www.cellectar.com/news-media/press-releases/detail/206/cellectar-receives-fda-fast-track-designation-for-clr-131

6. Cellectar receives FDA fast track designation for CLR 131 in diffuse large B-cell lymphoma. News release. Cellectar Biosciences. July 9, 2020. Accessed May 25, 2020. https://www.cellectar.com/news-media/press-releases/detail/211/cellectar-receives-fda-fast-track-designation-for-clr-131

7. Cellectar receives FDA fast track designation for CLR 131 in lymphoplasmacytic lymphoma/Waldenstroms macroglobulinemia. News release. Cellectar Biosciences. May 26, 2020. Accessed June 1, 2020. https://www.cellectar.com/news-media/press-releases/detail/238/cellectar-receives-fda-fast-track-designation-forclr-131

8. Alavi M, Hamidi M. Passive and active targeting in cancer therapy by liposomes and lipid nanoparticles. Drug Metab Pers Ther. 2019;34(1). doi:10.1515/dmpt-2018-0032

9. Yan W, Leung SS, To KK. Updates on the use of liposomes for active tumor targeting in cancer therapy. Nanomedicine (Lond). 2019;15(3):303-318. doi:10.2217/nnm-2019-0308

10. Jahan ST, Sadat SMA, Walliser M, Haddadi A. Targeted therapeutic nanoparticles: an immense promise to fight against cancer. J Drug Deliv. 2017;2017:9090325. doi:10.1155/2017/9090325

11. He H, Yuan D, Wu Y, Cao Y. Pharmacokinetics and pharmacodynamics modeling and simulation systems to support the development and regulation of liposomal drugs. Pharmaceutics. 2019;11(3):110. doi:10.3390/pharmaceutics11030110

12. Lancet JE, Uy GY, Newell LF, et al. Five-year final results of a phase 3 study of CPX-351 versus 7+3 in older adults with newly diagnosed high-risk/secondary acute myeloid leukemia. Presented at: 2020 European Hematology Association Virtual Congress; June 11-21, 2020. Abstract EP556.

13. Wainberg ZA, Bekaii-Saab T, Boland PM, et al. First-line liposomal irinotecan 5 fluorouracil/leucovorin oxaliplatin in patients with pancreatic ductal adenocarcinoma: primary analysis from a phase 1/2 study. Presented at: European Society of Medical Oncology World Congress on Gastrointestinal Cancer 2010; July 1-4, 2020. Abstract LBA-001.

14. EndoTAG-1. SynCoreBio. Accessed June 2, 2020. https://www.syncorebio.com/en/focus-area/sb05-endotag-1/

15. Jimeno A, Gupta S, Sullivan R, et al. A phase 1/2, open-label, multicenter, dose escalation and efficacy study of mRNA-2416, a lipid nanoparticle encapsulated mRNA encoding human OX40L, for intratumoral injection alone or in combination with durvalumab for patients with advanced malignancies. Presented at: 2020 American Association for Cancer Research Virtual Meeting I; April 27-28, 2020. Accessed June 1, 2020. Abstract CT032. https://www.abstractsonline.com/pp8/#!/9045/presentation/10742

16. Technology. LipoMedix. Accessed July 5, 2020. http://lipomedix.com/Products/Technology

17. Golombek SK, May JN, Theek B, et al. Tumor targeting via EPR: strategies to enhance patient responses. Adv Drug Deliv Rev. 2018;130:17-38. doi:10.1016/j.addr.2018.07.007

18. Yingchoncharoen P, Kalinowski DS, Richardson DR. Lipid-based drug delivery systems in cancer therapy: what is available and what is yet to come. Pharmacol Rev. 2016;68(3):701-787. doi:10.1124/pr.115.012070

19. Battaglia L, Ugazio E. Lipid nano- and microparticles: an overview of patent-related research. J Nanomater. 2019:1-22. doi:10.1155/2019/2834941

20. Barba AA, Bochicchio S, Dalmoro A, Lamberti G. Lipid delivery systems for nucleic-acid-based-drugs: from production to clinical applications. Pharmaceutics. 2019;11(8):360. doi:10.3390/pharmaceutics11080360

21. Liposomes and lipid nanoparticles as delivery vehicles for personalized medicine. Exelead. November 16, 2018. Accessed June 1, 2020. https://www.exeleadbiopharma.com/news/liposomes-and-lipid-nanoparticles-as-delivery-vehicles-for-personalized-medicine

22. BP1002 (liposomal Bcl2) for follicular lymphoma and other forms of non-Hodgkins lymphoma. Bio-Path Holdings. Accessed June 1, 2020. http://www.dnabilize.com/bp1002/

23. Prexigebersen (liposomal Grb2 antisense) for acute myeloid leukemia (AML). Bio-Path Holdings. Accessed June 1, 2020. http://www.dnabilize.com/bp1001

24. BP1003 (liposomal Stat3) for pancreatic cancer. Bio-Path Holdings. Accessed June 1, 2020. http://www.dnabilize.com/bp1003/

25. Bio-Path announces clinical update to interim analysis of phase 2 prexigebersen trial in acute myeloid leukemia. News release. Bio-Path Holdings. March 6, 2019. Accessed June 1, 2020. http://www.biopathholdings.com/wp-content/uploads/2019/03/BPTH_Press_Release_20190306.pdf

26. Bio-Path Holdings provides clinical update and 2020 business outlook. News release. Bio-Path Holdings. January 8, 2020. Accessed June 1, 2020. http://www.biopathholdings.com/wp-content/uploads/2020/01/BPTH_2020_Business_Outlook.pdf

27. Modernas pipeline. Moderna. Accessed June 2, 2020. https://www.modernatx.com/pipeline

28. Sreekanth V, Bajaj A. Recent advances in engineering of lipid drug conjugates for cancer therapy. ACS Biomater. Sci. Eng. 2019;5(9):4148-4166. doi:10.1021/acsbiomaterials.9b00689

29. Gabizon AA, Tahover E, Golan T, et al. Pharmacokinetics of mitomycin-c lipidic prodrug entrapped in liposomes and clinical correlations in metastatic colorectal cancer patients. Published online January 18, 2020. Invest New Drugs. doi:10.1007/s10637-020-00897-3

30. Deming DA, Maher ME, Leystra AA, et al. Phospholipid ether analogs for the detection of colorectal tumors. PLoS One. 2014;9(10):e109668. doi:10.1371/journal.pone.0109668

31. Weichert JP, Clark PA, Kandela IK, et al. Alkylphosphocholine analogs for broad-spectrum cancer imaging and therapy. Sci Transl Med. 2014;6(240):240ra75. doi:10.1126/scitranslmed.3007646

32. Li YC, Park MJ, Ye SK, Kim CW, Kim YN. Elevated levels of cholesterol-rich lipid rafts in cancer cells are correlated with apoptosis sensitivity induced by cholesterol-depleting agents. Am J Pathol. 2006;168(4):1107-1118. doi:10.2353/ajpath.2006.050959

33. Multi-asset product portfolio for treatment of various cancers. Cellectar Biosciences. Accessed May 25, 2020. https://www.cellectar.com/product-pipeline

34. Annual Report. Cellectar Biosciences. Accessed June 1, 2020. bit.ly/2CwItfO

35. Longcor J, Ailawadhi S, Oliver K, Callander N, Stiff P. CLR 131 demonstrates high rate of activity in a phase 1, dose escalation study in patients with relapsed or refractory multiple myeloma (RRMM). Clin Lymphoma Myeloma Leuk. 2019;19(suppl 10):E356-E357. doi:10.1016/j.clml.2019.09.589

Visit link:
CLR 131 Leads a New Generation of Lipid-Based Cancer Drug Delivery Systems - OncLive

Futurist Transhuman News Blog

Author Archives: Prof Baldwin

Detection dogs can help endangered native wildlife find a mate – ABC News

Reasons to be cheerful? Optimists live longer than pessimists – Independent.ie

The importance of having a primary care provider – Craig Daily Press

What the Bella twins typically eat in a day – Nicki Swift

5 Amazing Health Benefits of Pumpkin – MSN Money

Low Testosterone (Low T): Causes, Symptoms, Diagnosis …

Signs of Low Testosterone in Men Under 30

Monsoon immunity booster: Rev up healthy living with these tips – Hindustan Times

Healthy Living: What you need to know about the Menopause – Longford Leader

US coronavirus data will now go straight to the White House. Here’s what this means for the world – Stuff.co.nz

Calm and chill: What are the benefits of CBD Oil? – mtltimes.ca

IMA Official Says India’s Indigenous COVID-19 Vaccine to Reach Usable Stage Only After 2020 – The Weather Channel

Meet Moss, the detection dog helping Tassie devils find love – The Conversation AU

Delivering the power of nanomedicine to patients today – DocWire News

Solve Puzzles for Science | Foldit

Do you know about Andropause aka male menopause? – The Indian Express

Evolving habits – Daily Pioneer

Healthcare Nanotechnology (Nanomedicine) Market Forecasted To Surpass The Value Of US$ XX Mn/Bn By 2015 2021 – Jewish Life News

Northern youth group seeks speedy passage of Bill to establish National Innovation agency – Daily Sun

CLR 131 Leads a New Generation of Lipid-Based Cancer Drug Delivery Systems – OncLive